Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
暂无分享,去创建一个
Lucy J. Holt | Robin L. Jones | L. Pickering | C. Swanton | J. Nicod | S. Bhide | K. Harrington | A. Swerdlow | K. Edmonds | S. Gamblin | R. Wilkinson | D. Cunningham | Helen R. Flynn | A. Snijders | Susana Banerjee | E. Nicholson | S. Gandhi | J. Larkin | S. Jhanji | K. Tatham | C. Messiou | S. Turajlic | L. Au | E. Nye | H. Patel | J. Droney | N. Van As | J. MacRae | Sacheen Kumar | K. Wilkinson | I. Chau | L. Holt | R. Stone | G. Kassiotis | L. Cubitt | A. Água-Doce | L. Welsh | Z. Tippu | T. Slattery | M. Cerrone | A. Fendler | N. Starling | M. Pule | K. Young | I. Leslie | L. Boos | G. Cornish | S. Gennatas | A. Robinson | L. Mekkaoui | N. Yousaf | K. Rzeniewicz | A. Okines | Y. Khan | P. Hobson | R. Harvey | R. Goldstone | N. Joharatnam-Hogan | A. Reid | O. Curtis | Mary Y. Wu | A. Schmitt | S. Caidan | M. Crawford | F. Byrne | S. Banerjee | A. Furness | Wenyi Xie | W. Gordon | C. Gerard | S. Shepherd | M. O'Brien | S. Sarker | Robyn L. Shea | F. Gronthoud | Michael Howell | M. Mangwende | B. Shum | E. Carlyle | J. Bazin | K. Lingard | Hamid Ahmod | Mike Gavrielides | L. D. Rosario | B. Ward | K. Ng | Clemency Stephenson | Nicholas C. Turner | Camila Gomes | Nicholas C Turner | Mary Mangwende | Anna Robinson
[1] Robin L. Jones,et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.
[2] S. Sangrajrang,et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection , 2021, The Lancet Infectious Diseases.
[3] J. Klingström,et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.
[4] J. Münch,et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.
[5] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[6] E. Wherry,et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.
[7] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[8] K. Pradhan,et al. Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.
[9] E. Wherry,et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer , 2021, Nature Medicine.
[10] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[11] L. Piemonti,et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival , 2021, Nature Communications.
[12] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.
[13] J. Warner,et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium , 2021, Annals of Oncology.
[14] C. Swanton,et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains , 2021, bioRxiv.
[15] Evelien M. Adriaenssens,et al. CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes , 2021, Genome medicine.
[16] A. Harries,et al. Faculty Opinions recommendation of Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[17] D. Robertson,et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research , 2021, PLoS biology.
[18] P. McKay,et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.
[19] J. Zein,et al. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. , 2021, JAMA internal medicine.
[20] Gavin J. D. Smith,et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.
[21] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[22] A. Coolen,et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients , 2021, Cancer Cell.
[23] A. Achiron,et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies , 2021, Therapeutic advances in neurological disorders.
[24] K. Pradhan,et al. Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy , 2020, Nature Cancer.
[25] N. Rosenthal,et al. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19 , 2020, JAMA network open.
[26] Nguyen H. Tran,et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial , 2020, Nature Medicine.
[27] M. Nussenzweig,et al. Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.
[28] M. Malim,et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.
[29] G. Curigliano,et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 , 2020, Annals of Oncology.
[30] A. Iafrate,et al. COVID-19 neutralizing antibodies predict disease severity and survival , 2020, medRxiv.
[31] A. Sette,et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[32] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.
[33] Lisa E. Gralinski,et al. Animal models for COVID-19 , 2020, Nature.
[34] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[35] A. Swerdlow,et al. Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study , 2020, Cell.
[36] G. Curigliano,et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies , 2020, European Journal of Cancer.
[37] V. Jiménez‐Yuste,et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study , 2020, Journal of Hematology & Oncology.
[38] D. Kerr,et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.
[39] S. Mallal,et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.
[40] Nichollas E. Scott,et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 , 2020, Nature Medicine.
[41] K. Bhaskaran,et al. Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.
[42] Robin L. Jones,et al. Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer , 2020, European Journal of Cancer.
[43] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[44] A. Sette,et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.
[45] E. Robilotti,et al. Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.
[46] Robert L. Goldstone,et al. Scalable and robust SARS-CoV-2 testing in an academic center , 2020, Nature Biotechnology.
[47] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.
[48] V. Torri,et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.
[49] O. Schwartz,et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.
[50] Loise M. Francisco,et al. The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. , 2020, Cell reports.
[51] Alokkumar Jha,et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.
[52] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[53] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[54] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[55] Philip A. Ewels,et al. The nf-core framework for community-curated bioinformatics pipelines , 2020, Nature Biotechnology.
[56] M. Okano,et al. Cohort Study , 2020, Definitions.
[57] J. Bridgewater,et al. COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study , 2020, Therapeutic advances in medical oncology.
[58] S. Crotty. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.
[59] Paolo Di Tommaso,et al. Nextflow enables reproducible computational workflows , 2017, Nature Biotechnology.
[60] Jincun Zhao,et al. T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.
[61] A. Waisman,et al. PD‐1 signalling in CD4+ T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide‐induced tolerance , 2010, Immunology.
[62] V. Preedy,et al. Prospective Cohort Study , 2010 .